📊 SMTI Key Takeaways
Is Sanara MedTech Inc. (SMTI) a Good Investment?
Sanara MedTech demonstrates strong operational fundamentals with 19% revenue growth and exceptional 92.7% gross margins, but faces critical balance sheet distress. The company carries extreme leverage (7.74x D/E) with dangerously tight interest coverage (1.1x), providing virtually no safety margin. The $44.9M gap between operating income and net loss indicates substantial debt service burden and potential restructuring charges that threaten financial viability.
Why Buy Sanara MedTech Inc. Stock? SMTI Key Strengths
- Strong revenue growth of 19% YoY indicates solid market demand in orthopedic medical devices
- Exceptional gross margin of 92.7% demonstrates pricing power and operational efficiency
- Positive operating cash flow of $6.8M and free cash flow of $2.2M show underlying cash generation
- Adequate short-term liquidity with current ratio of 1.80x and cash balance of $16.6M
SMTI Stock Risks: Sanara MedTech Inc. Investment Risks
- Extreme financial leverage at 7.74x D/E with stockholders equity of only $5.9M provides minimal equity cushion
- Interest coverage ratio of 1.1x is critically low and leaves no margin for revenue decline or margin compression
- Net loss of -$37.6M despite positive operations signals unsustainable debt service and potential covenant violations
- Free cash flow margin of only 2.1% is insufficient to service $46M long-term debt; paydown would require 21+ years at current rates
Key Metrics to Watch
- Debt-to-equity ratio trajectory - must decline below 5.0x to reduce insolvency risk
- Interest coverage ratio - critical threshold is 2.0x; below 1.5x indicates imminent distress
- Operating margin sustainability - any decline below 7% directly threatens FCF and covenant compliance
- Debt refinancing activity and covenant waiver status with lenders
Sanara MedTech Inc. (SMTI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 2.1% FCF margin may limit capital allocation flexibility.
SMTI Profit Margin, ROE & Profitability Analysis
SMTI vs Healthcare Sector: How Sanara MedTech Inc. Compares
How Sanara MedTech Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sanara MedTech Inc. Stock Overvalued? SMTI Valuation Analysis 2026
Based on fundamental analysis, Sanara MedTech Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sanara MedTech Inc. Balance Sheet: SMTI Debt, Cash & Liquidity
SMTI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sanara MedTech Inc.'s revenue has grown significantly by 327% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.14 indicates the company is currently unprofitable.
SMTI Revenue Growth, EPS Growth & YoY Performance
SMTI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $21.7M | -$2.9M | $-0.34 |
| Q2 2025 | $20.2M | -$2.0M | $-0.23 |
| Q1 2025 | $18.5M | -$1.8M | $-0.21 |
| Q3 2024 | $16.0M | -$1.1M | $-0.13 |
| Q2 2024 | $15.8M | -$1.8M | $-0.22 |
| Q1 2024 | $15.5M | -$1.2M | $-0.14 |
| Q3 2023 | $13.0M | -$1.1M | $-0.13 |
| Q2 2023 | $9.7M | $769.4K | $0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sanara MedTech Inc. Dividends, Buybacks & Capital Allocation
SMTI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sanara MedTech Inc. (CIK: 0000714256)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SMTI
What is the AI rating for SMTI?
Sanara MedTech Inc. (SMTI) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SMTI's key strengths?
Claude: Strong revenue growth of 19% YoY indicates solid market demand in orthopedic medical devices. Exceptional gross margin of 92.7% demonstrates pricing power and operational efficiency.
What are the risks of investing in SMTI?
Claude: Extreme financial leverage at 7.74x D/E with stockholders equity of only $5.9M provides minimal equity cushion. Interest coverage ratio of 1.1x is critically low and leaves no margin for revenue decline or margin compression.
What is SMTI's revenue and growth?
Sanara MedTech Inc. reported revenue of $103.1M.
Does SMTI pay dividends?
Sanara MedTech Inc. pays dividends, with $0.2M distributed to shareholders in the trailing twelve months.
Where can I find SMTI SEC filings?
Official SEC filings for Sanara MedTech Inc. (CIK: 0000714256) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SMTI's EPS?
Sanara MedTech Inc. has a diluted EPS of $-4.36.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SMTI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Sanara MedTech Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SMTI stock overvalued or undervalued?
Valuation metrics for SMTI: ROE of -632.5% (sector avg: 15%), net margin of -36.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SMTI stock in 2026?
Our dual AI analysis gives Sanara MedTech Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SMTI's free cash flow?
Sanara MedTech Inc.'s operating cash flow is $6.8M, with capital expenditures of $4.6M. FCF margin is 2.1%.
How does SMTI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -36.4% (avg: 12%), ROE -632.5% (avg: 15%), current ratio 1.80 (avg: 2).
Is Sanara MedTech Inc. carrying too much debt?
SMTI has a debt-to-equity ratio of 7.74x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.80 suggests adequate short-term liquidity.